118 related articles for article (PubMed ID: 32307443)
1. Addition of an online, validated family history questionnaire to the Dutch FIT-based screening programme did not improve its diagnostic yield.
Roos VH; Kallenberg FGJ; van der Vlugt M; Bongers EJC; Aalfs CM; Bossuyt PMM; Dekker E
Br J Cancer; 2020 Jun; 122(12):1865-1871. PubMed ID: 32307443
[TBL] [Abstract][Full Text] [Related]
2. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
[TBL] [Abstract][Full Text] [Related]
3. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
[TBL] [Abstract][Full Text] [Related]
4. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
[TBL] [Abstract][Full Text] [Related]
5. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic yield of a risk model versus faecal immunochemical test only: a randomised controlled trial in a colorectal cancer screening programme.
Kortlever TL; van der Vlugt M; Duijkers FAM; Masclee A; Kraaijenhagen R; Spaander MCW; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E
Br J Cancer; 2023 Sep; 129(5):791-796. PubMed ID: 37468570
[TBL] [Abstract][Full Text] [Related]
7. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
[TBL] [Abstract][Full Text] [Related]
8. A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening.
Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mundt MW; Spijker WJ; Bongers EJC; Kuipers EJ; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
Gut; 2017 Nov; 66(11):1975-1982. PubMed ID: 27507905
[TBL] [Abstract][Full Text] [Related]
9. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
[TBL] [Abstract][Full Text] [Related]
10. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
Murphy J; Halloran S; Gray A
BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
[TBL] [Abstract][Full Text] [Related]
12. Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy.
Stegeman I; de Wijkerslooth TR; Stoop EM; van Leerdam ME; Dekker E; van Ballegooijen M; Kuipers EJ; Fockens P; Kraaijenhagen RA; Bossuyt PM
Gut; 2014 Mar; 63(3):466-71. PubMed ID: 23964098
[TBL] [Abstract][Full Text] [Related]
13. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round.
Digby J; Fraser CG; Carey FA; Diament RH; Balsitis M; Steele RJ
J Med Screen; 2017 Jun; 24(2):62-68. PubMed ID: 27370211
[TBL] [Abstract][Full Text] [Related]
14. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.
Stegeman I; van Doorn SC; Mundt MW; Mallant-Hent RC; Bongers E; Elferink MA; Fockens P; Stroobants AK; Bossuyt PM; Dekker E
Cancer Epidemiol; 2015 Jun; 39(3):388-93. PubMed ID: 25910865
[TBL] [Abstract][Full Text] [Related]
15. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
[TBL] [Abstract][Full Text] [Related]
16. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?
Haug U; Grobbee EJ; Lansdorp-Vogelaar I; Spaander MCW; Kuipers EJ
Gut; 2017 Jul; 66(7):1262-1267. PubMed ID: 27006184
[TBL] [Abstract][Full Text] [Related]
17. Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing.
van der Meulen MP; Toes-Zoutendijk E; Spaander MCW; Dekker E; Bonfrer JMG; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; van Velthuysen MF; Thomeer MGJ; van Veldhuizen H; de Koning HJ; Lansdorp-Vogelaar I; van Leerdam ME
PLoS One; 2022; 17(2):e0264067. PubMed ID: 35176116
[TBL] [Abstract][Full Text] [Related]
18. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
[TBL] [Abstract][Full Text] [Related]
19. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic accuracy of a quantitative faecal immunochemical test vs. symptoms suspected for colorectal cancer in patients referred for colonoscopy.
Tsapournas G; Hellström PM; Cao Y; Olsson LI
Scand J Gastroenterol; 2020 Feb; 55(2):184-192. PubMed ID: 31906738
[No Abstract] [Full Text] [Related]
[Next] [New Search]
